TY - JOUR T1 - The impact of breast cancer resistant protein (BCRP/ABCG2) on drug transport across Caco-2 cell monolayers JF - Drug Metabolism and Disposition JO - Drug Metab Dispos DO - 10.1124/dmd.119.088674 SP - dmd.119.088674 AU - Iichiro Kawahara AU - Satoyo Nishikawa AU - Akira Yamamoto AU - Yusuke Kono AU - Takuya Fujita Y1 - 2020/01/01 UR - http://dmd.aspetjournals.org/content/early/2020/03/19/dmd.119.088674.abstract N2 - Breast cancer resistant protein (BCRP) is expressed on the apical membrane of small intestinal epithelial cells and functions as an efflux pump with broad substrate recognition. Therefore, quantitative evaluation of the contribution of BCRP to the intestinal permeability of new chemical entities is very important in drug research and development. In this study, we assessed the BCRP-mediated efflux of several model drugs in Caco-2 cells using WK-X-34 as a dual inhibitor of P-glycoprotein (P-gp) and BCRP and LY335979 as a selective inhibitor of P-gp. The permeability of daidzein was high with an apparent permeability coefficient (PAB) for apical-to-basal transport of 20.3 × 10-6 cm/sec. In addition, its efflux ratio (ER) was 1.55, indicating that the contribution of BCRP to its transport is minimal. Estrone-3-sulfate and ciprofloxacin showed relatively higher ER values (>2.0), whereas their BCRP-related absorptive quotient (AQBCRP) was 0.21 and 0.3, respectively. These results indicate that BCRP does not play a major role in regulating the permeability of estrone-3-sulfate and ciprofloxacin in Caco-2 cells. Nitrofurantoin showed a PAB of 1.8 × 10-6 cm/sec, and its ER was 7.6. However, the AQBCRP was 0.37, suggesting minimal contribution of BCRP to nitrofurantoin transport in Caco-2 cells. In contrast, topotecan, SN-38, and sulfasalazine had low PAB values (0.81, 1.13, and 0.19 × 10-6 cm/sec, respectively), and each AQBCRP was above 0.6, indicating that BCRP significantly contributes to the transport of these compounds in Caco-2 cells. In conclusion, Caco-2 cells are useful to accurately estimate the contribution of BCRP to intestinal drug absorption.SIGNIFICANCE STATEMENT We performed an in vitro assessment of the contribution of BCRP to the transport of BCRP and/or P-gp substrates across Caco-2 cell monolayers using absorptive quotient (AQ), which has been proposed to represent the contribution of drug efflux transporters to the net efflux. The present study demonstrates that the combined use of a BCRP/P-gp dual inhibitor and a P-gp selective inhibitor is useful to estimate the impact of BCRP and P-gp on the permeability of tested compounds in Caco-2 cells. ER -